Le Lézard
Classified in: Health
Subjects: SVY, TRI

iDissection Classification Study to Evaluate Dissection Rate of FLEX Dynamic Scoring Cathetertm


TOLEDO, Ohio, Nov. 6, 2018 /PRNewswire/ -- VentureMed Group, Inc., a medical device company that develops and markets innovative interventional vascular solutions, announced the initiation of a new study to determine if the FLEX Dynamic Scoring Cathetertm reduces dissections and the need for bailout stents in peripheral arteries.  The study entitled "Arterial Dissections Following FLEX Scoring and Adjunctive Balloon Angioplasty: Intravascular Ultrasound Assessment and Correlation with Angiographic Findings" will utilize intravascular ultrasound (IVUS) to identify the health of the vessel after treatment.

(PRNewsfoto/VentureMed Group)

Nicolas W. Shammas, MD, Founder and Director of the Midwest Cardiovascular Research Foundation in Davenport, Iowa is the principal investigator for the study.  This study is the second iDissection study performed by Dr. Shammas.  The first study revealed that after atherectomy, in the peripheral arteries, significant dissections are more visible by a ratio of 6:1 when using IVUS in comparison to the typical angiogram.  Deducing that the presence and severity of dissection after atherectomy may have been underestimated, especially for deeper dissections which are associated with recurrent restenosis, recoil, and possibly acute closure.2

"After the indicative results of the initial iDissection study, I am motivated to look for vessel prep devices that further reduce the need for provisional stenting," said Dr. Shammas. "I am optimistic about the ability of the FLEX Catheter to reduce the rate of high-grade dissections and looking forward to the evaluation."

Using IVUS, the new study will evaluate the dissection rates of 15 patients following treatment of femoropopliteal denovo or no-stent restenosis by the FLEX Dynamic Scoring Cathetertm and plain old balloon angioplasty (POBA). 

"VentureMed Group is honored to be working with such an esteemed interventionalist and outstanding laboratory.  In over 400 registry case report forms, from multiple physicians that have reported on the performance of the FLEX Dynamic Scoring Cathetertm, we have seen low rates of minor dissections, less stents, and lower balloon inflation pressures required for lesion effacement.  As we embark on this new adjudicated study, we are confident Dr. Shammas will experience similar results." said John Pigott, MD, FACS, Jobst Vascular Institute, Promedica Healthcare Systems and Founder and Chief Science Officer of VentureMed Group. "We are anticipating improved outcomes that the FLEX positively impacts results as a safe and effective means of vessel prep in this iDissection study, along with future studies."

VentureMed Group will be exhibiting at Vascular Interventional Advances (VIVA), and the VEITH Symposium during the month of November.

About Peripheral Arterial Disease 
Peripheral Arterial Disease (PAD) is a narrowing of the peripheral arteries caused by a hardening of the arteries.  More than 12 million people in the US and 30 million people worldwide are affected by PAD.  It most commonly affects the arteries of the pelvis and legs, including the femoral and popliteal arteries. Left untreated, patients with PAD are five times more at risk for limb amputation.1

References:

  1. Stay in Circulation: Campaign Materials: Facts about Peripheral Arterial Disease (P.A.D.). Nhlbi.nih.gov. https://www.nhlbi.nih.gov/health/educational/pad/materials/pad_extfctsht_general.html. Published 2018. Accessed November 5, 2018.
  2. Nicolas W. Shammas, MD, MS, et al (2018). Intravascular Ultrasound Assessment and Correlation With Angiographic Findings Demonstrating Femoropopliteal Arterial Dissections Post Atherectomy: Results From the iDissection Study. [online] Journal of Invasive Cardiology. Available at: https://evtoday.com/2018/07/11/study-evaluates-ivus-for-detecting-dissections-in-femoropopliteal-vessels-after-pta [Accessed 5 Nov. 2018].

About the FLEX Dynamic Scoring Cathetertm 
The FLEX Catheter creates long parallel linear scores in all plaque morphologies to prepare an ideal vessel environment to facilitate angioplasty. Its dynamic technique safely scores difficult, diseased vessels, providing vessel compliance and acute lumen gain.

About VentureMed Group, Inc. 
VentureMed Group is a medical device company, founded in 2012, that develops and markets innovative medical devices for the interventional vascular industry.  The company's FLEX Dynamic Scoring Cathetertm is a safe and effective vessel preparation device engineered to create parallel micro-incisions, prepping the vessel for angioplasty. The FLEX Dynamic Scoring Cathetertm is cleared for sale in the US and carries CE Mark for sales in EU.  For more information, visit www.FlexVesselPrep.com.

Contact:

Gary L. Smith, CEO 
VentureMed Group, Inc. 
614-296-4213 
[email protected]

 

SOURCE VentureMed Group


These press releases may also interest you

at 02:54
HanxBio today announced that it has published a research article titled "Narazaciclib, a novel multikinase inhibitor with potent activity against CSF1R, FLT3 and CDK6, shows strong anti-AML activity in defined preclinical models" in the Nature...

at 02:50
International medical imaging IT and cybersecurity company Sectra (STO: SECT B) has signed two contracts to provide the radiology module of its enterprise imaging solution with two university medical centers in Germany?Universitätsklinikum Tübingen...

at 02:24
Today, 23 April 2024, the subscription period in SciBase Holding AB (publ) ('SciBase' or the 'Company') rights issue of units of up to approximately SEK 15 million commences (the 'Rights Issue'). The Rights Issue was resolved by the Board of...

at 02:05
Antech, the veterinary diagnostics company focused on partnering with veterinary professionals to predict, diagnose, and monitor wellness and disease, today announced the launch of the breakthrough in-hospital Nu.Q® Canine Cancer Test in Europe. A...

at 02:00
Red Arrow Therapeutics Inc. closed a $4.5M Seed Extension round, raising from four, top-tier institutional investors in Japan. Participants of this round are: Beyond Next Ventures Inc.The University of Tokyo Edge Capital Partners Co., Ltd.Keio...

at 01:05
Investment funds managed by KKR, a leading global investment firm, have agreed to acquire Immedica Pharma, a pharmaceutical company headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care...



News published on and distributed by: